share_log

Institutional Owners May Ignore Altimmune, Inc.'s (NASDAQ:ALT) Recent US$69m Market Cap Decline as Longer-term Profits Stay in the Green

Institutional Owners May Ignore Altimmune, Inc.'s (NASDAQ:ALT) Recent US$69m Market Cap Decline as Longer-term Profits Stay in the Green

機構所有者可能會忽略Altimmune, Inc.”s(納斯達克股票代碼:ALT)由於長期利潤保持增長,最近市值下降了6900萬美元
Simply Wall St ·  05/24 00:41

Key Insights

關鍵見解

  • Institutions' substantial holdings in Altimmune implies that they have significant influence over the company's share price
  • 50% of the business is held by the top 24 shareholders
  • Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock
  • 機構在Altimmune的大量持股意味着它們對公司的股價有重大影響
  • 50% 的業務由前 24 名股東持有
  • 所有權研究以及分析師預測數據有助於更好地了解股票的機會

If you want to know who really controls Altimmune, Inc. (NASDAQ:ALT), then you'll have to look at the makeup of its share registry. With 63% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

如果你想知道誰真正控制着Altimmune, Inc.(納斯達克股票代碼:ALT),那麼你必須看看其股票登記處的構成。機構擁有63%的股份,是公司的最大股份。也就是說,如果股票上漲,該集團將受益最大(如果股價下跌,則損失最大)。

Losing money on investments is something no shareholder enjoys, least of all institutional investors who saw their holdings value drop by 11% last week. Still, the 84% one-year gains may have helped mitigate their overall losses. But they would probably be wary of future losses.

投資虧損是任何股東都不喜歡的事情,更不用說上週持股價值下降11%的機構投資者了。儘管如此,84%的一年期漲幅可能有助於減輕他們的總體虧損。但是他們可能會對未來的損失保持警惕。

In the chart below, we zoom in on the different ownership groups of Altimmune.

在下圖中,我們放大了Altimmune的不同所有權組。

ownership-breakdown
NasdaqGM:ALT Ownership Breakdown May 23rd 2024
納斯達克通用汽車:ALT 所有權明細 2024 年 5 月 23 日

What Does The Institutional Ownership Tell Us About Altimmune?

關於Altimmune,機構所有權告訴我們什麼?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

機構在向自己的投資者報告時通常會根據基準來衡量自己,因此,一旦股票被納入主要指數,他們通常會對股票更加熱情。我們預計大多數公司都會有一些機構在冊,尤其是在它們正在成長的情況下。

As you can see, institutional investors have a fair amount of stake in Altimmune. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Altimmune, (below). Of course, keep in mind that there are other factors to consider, too.

如您所見,機構投資者在Altimmune中擁有相當數量的股份。這可能表明該公司在投資界具有一定程度的信譽。但是,最好謹慎行事,不要依賴機構投資者所謂的驗證。他們也是,有時候會弄錯。如果兩個大型機構投資者試圖同時拋售股票,股價大幅下跌的情況並不少見。因此,值得檢查一下Altimmune過去的收益軌跡(見下文)。當然,請記住,還有其他因素需要考慮。

earnings-and-revenue-growth
NasdaqGM:ALT Earnings and Revenue Growth May 23rd 2024
納斯達克通用汽車公司:ALT 收益和收入增長 2024 年 5 月 23 日

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Altimmune is not owned by hedge funds. Looking at our data, we can see that the largest shareholder is State Street Global Advisors, Inc. with 12% of shares outstanding. For context, the second largest shareholder holds about 5.7% of the shares outstanding, followed by an ownership of 4.4% by the third-largest shareholder.

機構投資者擁有公司50%以上的股份,因此加在一起可能會對董事會的決策產生重大影響。Altimmune 不歸對沖基金所有。從我們的數據來看,我們可以看到最大的股東是道富環球顧問公司,其已發行股份的12%。就背景而言,第二大股東持有約5.7%的已發行股份,其次是第三大股東持有4.4%的所有權。

Looking at the shareholder registry, we can see that 50% of the ownership is controlled by the top 24 shareholders, meaning that no single shareholder has a majority interest in the ownership.

查看股東登記處,我們可以看到50%的所有權由前24名股東控制,這意味着沒有一個股東在所有權中擁有多數權益。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

雖然研究公司的機構所有權可以爲您的研究增加價值,但研究分析師的建議以更深入地了解股票的預期表現也是一種好做法。有相當數量的分析師在報道該股,因此了解他們對未來的總體看法可能很有用。

Insider Ownership Of Altimmune

Altimmune 的內部所有權

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

不同國家對內部人士的定義可能略有不同,但董事會成員總是計算在內。公司管理層對董事會的回答,董事會應代表股東的利益。值得注意的是,有時高層管理人員自己也在董事會中。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

當內部所有權表明領導層像公司的真正所有者一樣思考時,內部所有權是積極的。但是,高度的內部所有權也可以賦予公司內部的一小部分人巨大的權力。在某些情況下,這可能是負面的。

Our information suggests that Altimmune, Inc. insiders own under 1% of the company. It seems the board members have no more than US$4.2m worth of shares in the US$546m company. Many investors in smaller companies prefer to see the board more heavily invested. You can click here to see if those insiders have been buying or selling.

我們的信息表明,Altimmune, Inc.內部人士擁有該公司不到1%的股份。看來董事會成員在這家價值5.46億美元的公司中持有的股份不超過420萬美元。許多小型公司的投資者更願意看到董事會加大投資力度。你可以點擊這裏查看這些內部人士是否在買入或賣出。

General Public Ownership

一般公有制

With a 36% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Altimmune. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Altimmune擁有36%的所有權,主要由個人投資者組成的公衆對Altimmune有一定程度的影響力。儘管這種所有權規模可能不足以影響對他們有利的政策決定,但它們仍然可以對公司政策產生集體影響。

Next Steps:

後續步驟:

It's always worth thinking about the different groups who own shares in a company. But to understand Altimmune better, we need to consider many other factors. Case in point: We've spotted 5 warning signs for Altimmune you should be aware of, and 2 of them are concerning.

擁有公司股份的不同群體總是值得考慮的。但是,爲了更好地了解Altimmune,我們需要考慮許多其他因素。一個很好的例子:我們發現了你應該注意的5個Altimmune警告信號,其中兩個是令人擔憂的。

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

如果你想了解分析師對未來增長的預測,千萬不要錯過這份關於分析師預測的免費報告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論